News and Announcements

All | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

Displaying 1 - 20 of 140
Amsterdam UMC Joins the ICPC

June 13th, 2019 marked the addition of our 33rd institution to the International Cancer Proteogenomic Consortium (ICPC).  We are pleased to include Amsterdam UMC as a participant in the global effort to accelerate cancer research.


The National Cancer Center - Korea (NCC-K) Joins the International Cancer Proteogenomic Consortium (ICPC)

The National Cancer Center - Korea (NCC-K) joins the International Cancer Proteogenome Consortium (ICPC) global partnership.  The NCC-K has joined the ranks of 31 institutions in 12 countries around the world that have previously made this commitment with the


Proteomic Dataset Release of the CPTAC and CBTTC Collaborative Pediatric Brain Tumor Pilot Study

While it’s a common misconception that all tumors in the brain are the same, there are more than 120 subtypes of brain cancers with very diverse features and diagnosis.


Dr. Rodriguez Speaks at JSN, Fujita, and Nagoya University about the Power of Proteogenomics

Dr. Henry Rodriguez gave the keynote address at the 62nd Annual Meeting of the Japanese Society of Nephrology in Nagoya, Japan this week.  In line with the conference’s theme Open The Future, Dr.


The Magic of Proteogenomics Explained Series: CPTAC Proteogenomics Program

Since its first mention in the scientific literature in 2004 by Jaffe et al1, the term proteogenomics has been shrouded in mystery and thick technical language.  It is a complex idea, but one that is gaining traction as its value to improve our understanding of cancer development and potentially...


CPTAC Develops a New Technique (BASIL) to Enhance Phospho Sensitivity from a Small Population of Cells (feasibility on human pancreatic islets)

Phosphorylation is a key process in the regulation of protein activity and has long been appreciated as an essential mechanism for the control of cellular function - tells a protein where to go, what to bind to and even when to die.


CPTAC Releases Lung Adenocarcinoma (LUAD) Proteomic Dataset

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) is pleased to release its newest comprehensive dataset - deep proteomic/phosphoproteomic data and imaging data of Lung Adenocarcinoma (LUAD) patient tumors.  The CPTAC Tumor Characterization Program uses proteogenomic analysis to systematic...


Congratulations to the Best Performers of the precisionFDA/NCI-CPTAC Crowdsourced Multi-omics Sample Mislabeling Correction Big Data Challenge

Riding the wave of the future requires scientists to move away from silo-thinking to an inclusive and collaborative mind set. By leveraging the power of crowdsourcing, precisionFDA and NCI-CPTAC teamed up to launch the Multi-omics Enabled Sample Mislabeling Correction Big Data Challenge. Over 500...


CPTAC Researchers Analyze Colon Cancer Proteins and Genes to Uncover New Potential Treatments

Analyzing both the entire set of genes and all the proteins produced by colon cancer tissues from patient samples has revealed a more comprehensive view of the tumor that points at novel cancer biological mechanisms and possible new therapeutic strategies.


Perspective on the clinical potential of mass spectrometry-based proteogenomics

Is DNA sequencing enough to recommend personalized treatments for cancer patients? In a article published in Nature Reviews Clinical Oncology, CPTAC investigators and colleagues from the Fred Hutch, Baylor College of Medicine, and University of Washington Medicine make the case for proteogenomics...


CPTAC Genomic Data Now Available in the NCI Genomic Data Commons (GDC)

CPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. The overarching goal of CPTAC is to improve our ability to diagnose, treat and prevent cancer....


Be Part of Tomorrow’s Next-Gen Big Data Scientists (BD-STEP Training Fellowship Announcement)

"Big data" is a term to describe data sets so large or complex that traditional data processing strategies are inadequate. As continued advancements in biomedical technologies generate an increasing amount of patient data, administration of patient-centered care will depend, in part, on the abili...


precisionFDA/NCI-CPTAC Challenge Top Performers to Present at RECOMB2019 DREAM Satellite Conference

In February 2019, the precisionFDA and the National Cancer Institute’s (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) (in coordination with DREAM Challenges) proudly announced the best performers in the first-ever Crowdsourced Multi-omics Sample Mislabeling Big Data Challenge.


CPTAC Researchers Develop A Freely Available Database for Phosphosite-Specific Signature Analysis

It is no coincidence that one cellular process is mentioned time and time again in discussions of cell-signaling pathways in cancer - that is phosphorylation. Since its discovery, it has come to be recognized as a global regulator of many intracellular processes such as growth, proliferation, and...


Best Performers Announced! - precisionFDA NCI-CPTAC Crowdsourced Multi-omics Sample Mislabeling Big Data Challenge

In biomedical research, sample mislabeling, or incorrect annotation has been a long-standing problem that contributes to irreproducible results and invalid conclusions. These problems are particularly prevalent in large scale multi-omics studies where human errors could arise during sample transf...


Researchers Team Up to Catalog the Landscape of Circular RNA in Cancer

University of Michigan Rogel Cancer Center researchers Arul Chinnaiyan, Alexey Nesvizhskii and colleagues have recently teamed up to catalog circular RNA (circRNA) in multiple cancers and conducted initial research that suggests these stable structures could serve as cancer markers in blood or ur...


CPTAC Develops PepQuery for Novel Peptide Identification and Validation

Integrative proteogenomic methods use mass spectrometry (MS)-based proteomic database for identifying new genomic alterations and validating novel protein sequences as potential disease biomarkers or therapeutic targets. The customized database approach is time consuming and not feasible for real...


Update on Behalf of NCI’s Cancer Imaging Program (New CPTAC Histopathology Images)

Built on a continuous partnership between National Cancer Institute’s (NCI’s) Cancer Imaging Program and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), NCI’s The Cancer Imaging Archive (TCIA) releases a newly improved CPTAC histopathology interface. The interface hosts histopathology i...


NCI Proteomics Assay Portal Releases 660 Mouse MRM-MS Plasma Assays

Built on a continuous partnership between National Cancer Institute (NCI) and the University of Victoria Genome British Columbia Proteomics Centre, NCI’s CPTAC Assay Portal releases 660 mouse multiple reaction monitoring-mass spectrometry (MRM-MS) plasma assays to the community.


ICPC Korea University Team Proteogenomically Characterizes Early-Onset Gastric Cancer

The incidence of early-onset gastric cancer (EOGC), a type of cancer that occurs in younger patients and found throughout the stomach, is markedly elevated in the Republic of Korea. As a country with the highest rates worldwide in both sexes, there is a need to identify molecular signature...


Pages